Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Certara (CERT)

Certara: President of Drug Development Solutions Patrick Smith steps down March 3

Neutral Impact 2 of 5 leadership Written later

Certara said Dr. Patrick F. Smith stepped down as President of Certara Drug Development Solutions effective March 3, 2025. He will remain with the company in a senior advisory and scientific role. The filing does not name a successor or describe any change to financial results.

Key points

  • Dr. Patrick F. Smith stepped down as President, Certara Drug Development Solutions, effective March 3, 2025
  • Smith will remain employed by Certara in a senior advisory and scientific role
  • The filing was dated March 5, 2025 and does not name a replacement

The filing

CompanyCertara (CERT)
Form8-K, current report
Filed with the SECMar 5, 2025, 4:24 PM ET
Accession number0001827090-25-000018

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.